The Effect of Systemic Steroid Use on the Success of Core Decompression in Non-Traumatic Early-Stage Femoral Head Osteonecrosis.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Medical Bulletin of Sisli Etfal Hospital Pub Date : 2026-03-23 eCollection Date: 2026-01-01 DOI:10.14744/SEMB.2025.04207
Gokhan Pehlivanoglu, Osman Cimen, Alper Koksal
{"title":"The Effect of Systemic Steroid Use on the Success of Core Decompression in Non-Traumatic Early-Stage Femoral Head Osteonecrosis.","authors":"Gokhan Pehlivanoglu, Osman Cimen, Alper Koksal","doi":"10.14744/SEMB.2025.04207","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Systemic corticosteroid use is a well-established risk factor for non-traumatic osteonecrosis of the femoral head (ONFH). However, its impact on the clinical outcomes of joint-preserving procedures, such as core decompression (CD), remains uncertain. This study aimed to evaluate whether systemic steroid exposure influences the success of CD in patients with early-stage ONFH.</p><p><strong>Methods: </strong>This retrospective cohort study included 49 hips from 41 patients with Ficat stage IIa ONFH who underwent isolated CD between 2013 and 2021. Patients were stratified into two groups according to systemic corticosteroid use within one year prior to diagnosis. Demographic and radiologic data, including modified Kerboul angle and stage, were collected. Treatment success was defined as the absence of femoral head collapse or conversion to total hip arthroplasty at the final radiologic follow-up. Outcomes were compared between steroid users and non-users using t-tests, Mann-Whitney U, chi-square, and Fisher's exact tests, as appropriate.</p><p><strong>Results: </strong>Overall, treatment success was achieved in 63.3% of hips. The success rate was 70.4% in steroid users and 54.5% in non-users, but this difference was not statistically significant (p=0.372). Baseline radiologic parameters, including modified Kerboul angle and stage, did not differ significantly. Sex distribution differed significantly (p=0.003), while age, follow-up duration, and bilaterality were comparable.</p><p><strong>Conclusion: </strong>Systemic corticosteroid use was not significantly associated with worse radiologic outcomes following CD in early-stage ONFH. These findings support CD as a viable joint-preserving treatment in appropriately selected patients, irrespective of prior steroid exposure.</p>","PeriodicalId":42218,"journal":{"name":"Medical Bulletin of Sisli Etfal Hospital","volume":"60 1","pages":"79-84"},"PeriodicalIF":0.9000,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13077188/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Bulletin of Sisli Etfal Hospital","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/SEMB.2025.04207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Systemic corticosteroid use is a well-established risk factor for non-traumatic osteonecrosis of the femoral head (ONFH). However, its impact on the clinical outcomes of joint-preserving procedures, such as core decompression (CD), remains uncertain. This study aimed to evaluate whether systemic steroid exposure influences the success of CD in patients with early-stage ONFH.

Methods: This retrospective cohort study included 49 hips from 41 patients with Ficat stage IIa ONFH who underwent isolated CD between 2013 and 2021. Patients were stratified into two groups according to systemic corticosteroid use within one year prior to diagnosis. Demographic and radiologic data, including modified Kerboul angle and stage, were collected. Treatment success was defined as the absence of femoral head collapse or conversion to total hip arthroplasty at the final radiologic follow-up. Outcomes were compared between steroid users and non-users using t-tests, Mann-Whitney U, chi-square, and Fisher's exact tests, as appropriate.

Results: Overall, treatment success was achieved in 63.3% of hips. The success rate was 70.4% in steroid users and 54.5% in non-users, but this difference was not statistically significant (p=0.372). Baseline radiologic parameters, including modified Kerboul angle and stage, did not differ significantly. Sex distribution differed significantly (p=0.003), while age, follow-up duration, and bilaterality were comparable.

Conclusion: Systemic corticosteroid use was not significantly associated with worse radiologic outcomes following CD in early-stage ONFH. These findings support CD as a viable joint-preserving treatment in appropriately selected patients, irrespective of prior steroid exposure.

非外伤性早期股骨头坏死患者全身性类固醇应用对核心减压成功的影响。
目的:全身使用皮质类固醇是非创伤性股骨头骨坏死(ONFH)的一个公认的危险因素。然而,它对关节保留手术(如椎体减压)的临床结果的影响仍不确定。本研究旨在评估全身性类固醇暴露是否会影响早期ONFH患者CD的成功。方法:这项回顾性队列研究包括41例Ficat期IIa期ONFH患者的49髋,这些患者在2013年至2021年间接受了孤立性CD。根据诊断前一年的全身皮质类固醇使用情况,将患者分为两组。收集了人口统计学和放射学资料,包括改进的kerboll角和分期。治疗成功的定义是在最后的放射学随访中没有股骨头塌陷或转向全髋关节置换术。使用t检验、Mann-Whitney U检验、卡方检验和Fisher精确检验比较类固醇使用者和非使用者的结果。结果:总体而言,治疗成功率为63.3%。类固醇使用者的成功率为70.4%,非类固醇使用者的成功率为54.5%,但差异无统计学意义(p=0.372)。基线放射学参数,包括改良的Kerboul角和分期,没有显著差异。性别分布差异显著(p=0.003),而年龄、随访时间和双侧性具有可比性。结论:全身性使用皮质类固醇与早期ONFH患者CD后较差的影像学结果无显著相关。这些发现支持CD作为一种可行的关节保留治疗方法,适用于适当选择的患者,与既往的类固醇暴露无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical Bulletin of Sisli Etfal Hospital
Medical Bulletin of Sisli Etfal Hospital MEDICINE, GENERAL & INTERNAL-
自引率
16.70%
发文量
41
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书